RNAC

Cartesian Therapeutics, Inc. Common Stock

6.89

USD

-0.13

-1.85%

Nov 10, 15:59 UTC -5

Closed

After-Market

6.88

0.00

-0.07%

Cartesian Therapeutics, Inc. Common Stock (RNAC) Profile

Cartesian Therapeutics, Inc. Common Stock Profile

About

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.

Info & Links

CEO

Carsten Brunn

Headquarters

7495 New Horizon Way
Frederick, MD 21703, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

102

Employees

Cartesian Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

210.01M

Enterprise Value

137.26M

Enterprise Value/EBITDA(ttm)

-0.88

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

116.25

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

-5356.28%

Profit Margin(ttm)

-14932.88%

Return on Equity(ttm)

Return on Invested Capital(ttm)

92.29%

Return on Assets(ttm)

-29.84%

Income Statement

Revenue(ttm)

1.02M

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

1.02M

EBITDA(ttm)³

-156.51M

Net Income Available to Common(ttm)

-126.88M

Diluted EPS(ttm)

-4.94

Share Statistics

Beta (5Y Monthly)

0.74

52-Week Change

-12.45%

S&P 500 52-Week Change

16.37%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

30.50M

Dividend Yield

0.00%

Float⁴

19.00M

% Held by Insiders

37.20%

% Held by Institutions

86.95%

Balance Sheet

Total Cash(mrq)

122.97M

Total Cash Per Share(mrq)

4.03

Total Debt(mrq)

50.22M

Total Debt/Equity(mrq)

-38.49%

Current Ratio(mrq)

8.38%

Quick Ratio(mrq)

7.48%

Book Value Per Share(mrq)

-4.28

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.34

Free Cash Flow(ytd)

-71.69M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.